Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Stock Down 0.2 %

NASDAQ:MRNS opened at $0.55 on Thursday. Marinus Pharmaceuticals has a 52-week low of $0.22 and a 52-week high of $8.45. The stock’s 50 day moving average price is $0.55 and its 200 day moving average price is $0.68. The company has a market capitalization of $30.32 million, a PE ratio of -0.22 and a beta of 1.03.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Beryl Capital Management LLC acquired a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth about $2,262,000. Franklin Resources Inc. lifted its position in Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after acquiring an additional 1,219,871 shares during the period. Woodline Partners LP grew its stake in shares of Marinus Pharmaceuticals by 84.7% in the 4th quarter. Woodline Partners LP now owns 2,335,681 shares of the biopharmaceutical company’s stock valued at $1,250,000 after purchasing an additional 1,071,410 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Marinus Pharmaceuticals by 266.1% in the fourth quarter. JPMorgan Chase & Co. now owns 487,584 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 354,393 shares during the period. Finally, XTX Topco Ltd raised its stake in shares of Marinus Pharmaceuticals by 1,564.7% during the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 206,614 shares during the last quarter. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.